Biogen (NASDAQ:BIIB) Given New $200.00 Price Target at Sanford C. Bernstein

Key Points

• Sanford C. Bernstein trimmed its price target on Biogen to $200 from $201, implying about a 5.27% upside from the current share price.
• Analyst sentiment is mixed: the stock's average rating is "Hold" with an average target of $213.85, based on 14 Buy, 13 Hold and 1 Sell recommendations.
• Biogen beat quarterly expectations with EPS of $3.57 (vs. $2.95 est.) and revenue of $2.48B (vs. $2.29B est.), and set FY2026 guidance of $14.25–$15.25 EPS (consensus ~14.91).

Biogen (NASDAQ:BIIB - Get Free Report) had its target price reduced by investment analysts at Sanford C. Bernstein from $201.00 to $200.00 in a note issued to investors on Thursday,MarketScreener reports. Sanford C. Bernstein's price objective indicates a potential upside of 5.27% from the company's current price.

A number of other research analysts have also recently weighed in on the stock. Wedbush boosted their price objective on shares of Biogen from $191.00 to $196.00 and gave the company a "neutral" rating in a research report on Thursday. Barclays assumed coverage on shares of Biogen in a research report on Thursday, February 19th. They set an "equal weight" rating and a $185.00 price objective on the stock. Citigroup restated a "neutral" rating on shares of Biogen in a report on Friday. Royal Bank Of Canada upped their price target on shares of Biogen from $213.00 to $222.00 and gave the stock an "outperform" rating in a report on Thursday. Finally, Truist Financial cut their price target on shares of Biogen from $193.00 to $189.00 and set a "hold" rating on the stock in a report on Monday, April 13th. Fourteen investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $213.85.

Biogen Trading Up 0.4%

BIIB stock traded up $0.71 during mid-day trading on Thursday, reaching $189.99. 65,672 shares of the stock traded hands, compared to its average volume of 1,317,165. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 3.06. Biogen has a one year low of $115.25 and a one year high of $202.41. The stock has a market capitalization of $27.88 billion, a PE ratio of 20.39, a PEG ratio of 1.63 and a beta of 0.16. The business has a 50-day moving average price of $184.52 and a two-hundred day moving average price of $176.06.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating analysts' consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion for the quarter, compared to analysts' expectations of $2.29 billion. During the same quarter in the previous year, the business posted $3.02 earnings per share. The business's revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts expect that Biogen will post 14.91 EPS for the current year.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rothschild Investment LLC grew its holdings in shares of Biogen by 12.3% during the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company's stock valued at $90,000 after buying an additional 56 shares in the last quarter. Itau Unibanco Holding S.A. grew its stake in Biogen by 24.4% in the fourth quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 66 shares in the last quarter. Advisory Services Network LLC grew its stake in Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company's stock valued at $251,000 after purchasing an additional 68 shares in the last quarter. CVA Family Office LLC grew its stake in Biogen by 18.1% in the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company's stock valued at $65,000 after purchasing an additional 71 shares in the last quarter. Finally, Davis Investment Partners LLC grew its stake in Biogen by 1.7% in the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company's stock valued at $778,000 after purchasing an additional 71 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.